All News

eClinical Solutions' chief delivery officer highlights challenges and opportunities for innovation and health equity.

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its dual role in promoting tumor cell migration and shaping a protective tumor microenvironment.

In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, Pfizer strengthens focus through strategic partnerships and spin-offs, and CMS launches a new initiative to reduce Medicaid drug costs.

FDA introduces a new drug approval process, the Plausible Mechanism Pathway, streamlining drug approvals for personalized therapies targeting rare genetic diseases without traditional trials.

As FDA fast-tracks GLP-1 treatments under its new pilot National Priority Voucher program, WeightWatchers prepares to position itself to compete in the fast-evolving weight-loss drug market driven by affordability and accessibility.

Ovid Therapeutics and Metagenomi unveil leadership changes and financial results, highlighting strategic shifts and future growth opportunities in biotech.

Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations.

Following the removal of George Tidmarsh, HHS and FDA has appointed Richard Pazdur, M.D., director of CDER.

How the Metsera deal extends Pfizer’s 25-year blueprint for growth.

The stock increased after positive Q3 earnings and deals with the Trump administration.

The Swiss region hopes to attract pharma companies looking to escape uncertainty in the US market.

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.

Novo Nordisk presented the findings at the AASLD 76th annual meeting.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, the industry’s growing interest in direct-to-patient wholesale models, and the FDA’s expansion of its National Priority Voucher program to accelerate review of critical therapies.

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements collectively valued at more than $1.6 billion in potential milestone payments.

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices with global standards, reduce prescription spending, and strengthen the program’s long-term sustainability through fairer state purchasing and transparent pricing rules.

Metsera finalizes a $10 billion merger with Pfizer after rejecting Novo Nordisk's bids amid legal concerns to ensure shareholder value and regulatory safety.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block Kenvue’s dividend payment, and the FDA approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma.

The FDA has added six new therapies to its Commissioner’s National Priority Voucher program, bringing the total to 15 products that address major public health needs, including obesity, cancer, sickle cell disease, and drug-resistant tuberculosis.

Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% reduction in disease progression or death.

As leading drugmakers launch direct-to-patient platforms with steep discounts and digital care bundles, a new channel dynamic is emerging that gives manufacturers greater control of patient engagement while redefining, but not replacing, the strategic role of traditional wholesalers.

The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are transforming pharma’s next frontier in commercial customer engagement.

FDA’s approval of Caplyta as an adjunctive treatment to oral antidepressants for major depressive disorder in adults, expands the drug’s use to a fourth indication following positive Phase III trial results.

GLP-1 medications will be available on TrumpRx for discounted rates.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

The motion is part of the state’s lawsuit against the Tylenol-maker based on unproven autism claims.

From CRM saturation to commercial orchestration.